Name
GS1-09: Sacituzumab Govitecan vs. Chemotherapy as First Therapy After Endocrine Therapy in HR+/HER2- (IHC 0, 1+, 2+/ISH-) Metastatic Breast Cancer: Primary Results From ASCENT-07 Commentary by: Kevin Kalinsky, MD, MS, FASCO
Date & Time
Tuesday, December 2, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL